Sulfadar (sulfadoxine + pyrimethamine): Uses, Dosage & Side Effects

What it's for (Indications)

Sulfadoxine + pyrimethamine, often marketed under brand names such as Malaridox, is primarily indicated for the treatment of uncomplicated *Plasmodium falciparum* malaria in areas where the parasite exhibits resistance to other antimalarials, particularly chloroquine.
It is also utilized for intermittent presumptive treatment (IPT) of malaria in specific populations, such as pregnant women (IPTp) and infants (IPTi), in regions with high malaria transmission, as part of a broader malaria control strategy.
The drug's utility has diminished in many areas due to widespread parasite resistance, necessitating careful consideration of local resistance patterns before prescribing.
Its application is generally reserved for situations where first-line therapies are unsuitable or ineffective.
This combination therapy targets the parasitic folate synthesis pathway crucial for survival and replication, effectively interrupting the parasite's life cycle in the human host and alleviating clinical symptoms of malaria.

Dosage Information

Type	Guideline
Standard	The dosage of sulfadoxine + pyrimethamine is typically administered as a single oral dose for the treatment of uncomplicated P. falciparum malaria. For adults, a common regimen involves 500 mg sulfadoxine and 25 mg pyrimethamine. Pediatric dosages are determined by weight or age, with specific guidelines recommending appropriate fractions of the adult dose; for instance, children aged 1-3 years might receive a quarter tablet, 4-8 years a half tablet, and 9-14 years three-quarters of a tablet. In the context of Intermittent Presumptive Treatment in pregnancy (IPTp), the World Health Organization (WHO) recommends a full adult dose administered at scheduled intervals, starting from the second trimester. It is crucial to administer the full dose to prevent treatment failure and the development of drug resistance. Patients should be advised to take the medication with food or milk to minimize gastrointestinal discomfort. The precise dosing regimen should always adhere to local treatment guidelines and national malaria control programs, considering the specific epidemiological context and patient characteristics.

Type

Guideline

Standard

The dosage of sulfadoxine + pyrimethamine is typically administered as a single oral dose for the treatment of uncomplicated *P. falciparum* malaria. For adults, a common regimen involves 500 mg sulfadoxine and 25 mg pyrimethamine. Pediatric dosages are determined by weight or age, with specific guidelines recommending appropriate fractions of the adult dose; for instance, children aged 1-3 years might receive a quarter tablet, 4-8 years a half tablet, and 9-14 years three-quarters of a tablet. In the context of Intermittent Presumptive Treatment in pregnancy (IPTp), the World Health Organization (WHO) recommends a full adult dose administered at scheduled intervals, starting from the second trimester. It is crucial to administer the full dose to prevent treatment failure and the development of drug resistance. Patients should be advised to take the medication with food or milk to minimize gastrointestinal discomfort. The precise dosing regimen should always adhere to local treatment guidelines and national malaria control programs, considering the specific epidemiological context and patient characteristics.

Safety & Warnings

Common Side Effects

Sulfadoxine + pyrimethamine can elicit a range of side effects, varying in severity.
Common adverse reactions frequently involve the gastrointestinal system, presenting as nausea, vomiting, abdominal pain, and diarrhea.
Dermatological manifestations are also common and include pruritus, rash, and urticaria.
More serious, albeit rare, dermatological reactions can occur, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which are life-threatening mucocutaneous conditions requiring immediate medical attention.
Hematologic abnormalities, including megaloblastic anemia, leukopenia, agranulocytosis, and aplastic anemia, are potential risks, primarily due to pyrimethamine's antifolate activity, especially in individuals with pre-existing folate deficiency.
Hepatic dysfunction, characterized by elevated liver enzymes or, rarely, hepatic necrosis, has been reported.
Renal impairment, including crystalluria and acute kidney injury, particularly in dehydrated patients, is another concern.
Central nervous system effects such as headache, dizziness, and insomnia may also occur.
Patients should be thoroughly counseled on potential side effects and advised to seek immediate medical care for any severe or persistent reactions, particularly skin eruptions, fever, or unusual bleeding/bruising.

Serious Warnings

Black Box Warning: **Serious Warnings** While sulfadoxine + pyrimethamine does not carry a formal FDA Black Box Warning, its use is associated with a risk of severe, life-threatening, and sometimes fatal adverse reactions that warrant explicit cautionary statements. Physicians and patients must be acutely aware of these risks. **Severe Dermatologic Reactions:** This medication can cause severe and potentially fatal dermatologic reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). These reactions typically begin with a rash, which can rapidly progress to extensive blistering and exfoliation of the skin and mucous membranes. Patients developing any rash, especially if accompanied by fever, malaise, or mucosal involvement, should immediately discontinue the drug and seek urgent medical attention. Early discontinuation is critical for improving outcomes. **Hematologic Toxicities:** Sulfadoxine + pyrimethamine, particularly due to its antifolate activity, can lead to severe hematologic abnormalities, including megaloblastic anemia, leukopenia, agranulocytosis, and aplastic anemia. These conditions can be life-threatening. Close monitoring of complete blood counts (CBCs) is essential, especially in patients with pre-existing hematologic disorders, folate deficiency, or prolonged treatment courses. The drug should be immediately discontinued if significant hematologic abnormalities are observed. **Hepatic and Renal Toxicity:** Severe hepatotoxicity, including hepatic necrosis, and significant renal impairment, including acute kidney injury and crystalluria, have been reported. Patients should be monitored for signs of liver or kidney dysfunction, and the drug should be used with extreme caution in individuals with pre-existing hepatic or renal disease. These severe adverse events underscore the importance of careful patient selection, thorough counseling, and diligent monitoring during sulfadoxine + pyrimethamine therapy. The benefits of treatment must be carefully weighed against these significant potential risks.
Patients receiving sulfadoxine + pyrimethamine require careful monitoring for the development of severe adverse reactions.
Hypersensitivity reactions, ranging from mild skin rashes to severe dermatologic conditions like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported and can be fatal.
Any onset of rash should prompt immediate discontinuation of the drug.
Hematological toxicities, including megaloblastic anemia, leukopenia, agranulocytosis, and aplastic anemia, are significant concerns due to the drug's antifolate properties.
Regular monitoring of complete blood counts is advisable, especially during prolonged treatment or in patients predisposed to folate deficiency.
The medication should be used with extreme caution in patients with pre-existing folate deficiency, severe renal or hepatic impairment, or glucose-6-phosphate dehydrogenase (G6PD) deficiency, as these conditions increase the risk of adverse events like hemolytic anemia.
Pregnant and breastfeeding women should only use this combination when the potential benefits outweigh the risks, and under strict medical supervision, due to potential teratogenicity and neonatal toxicity, respectively.
Patients must be advised to report any signs of unusual bleeding, bruising, fever, sore throat, or jaundice immediately.

How it Works (Mechanism of Action)

Sulfadoxine and pyrimethamine act synergistically to inhibit the folic acid synthesis pathway in the *Plasmodium falciparum* parasite, which is essential for its nucleic acid synthesis and subsequent survival and replication. Sulfadoxine, a sulfonamide, competitively inhibits dihydropteroate synthase, an enzyme responsible for converting para-aminobenzoic acid (PABA) into dihydropteroic acid. This step is crucial for the parasite's de novo synthesis of folic acid, which it cannot obtain from its human host. Pyrimethamine, a dihydrofolate reductase inhibitor, then blocks the subsequent step in the pathway by inhibiting dihydrofolate reductase, an enzyme that converts dihydrofolate to tetrahydrofolate. Tetrahydrofolate is a critical coenzyme involved in various metabolic processes, including the synthesis of purines and pyrimidines, which are the building blocks of DNA and RNA. By sequentially blocking these two vital enzymes in the folate pathway, the combination of sulfadoxine and pyrimethamine effectively starves the parasite of essential precursors, leading to its demise. This dual mechanism confers a synergistic effect, enhancing antimalarial efficacy and helping to overcome emerging resistance by targeting two different points in the same biochemical pathway.